Cell's fight against cancer revealed

By the painstaking use of X-ray crystallography to track motion in very large molecules, a University of Southern California-led research group has taken a first look at the life-or-death struggle of a cancer-causing protein – LTag – and a key tumor suppressor – p53.

Each villainous LTag (short for large T antigen) single-handedly ties up a tag-team of six p53 molecules, inhibiting their tumor-suppressant role, the researchers report in the Sept. 1 issue of Genes & Development.

Undeterred, the p53 fight back by preventing replication of the virus that produces LTag, known as an oncoprotein for its function in cancer growth.

The champion depends on which side is stronger and healthier.

"If you have a lot of functional p53, you can override large T antigen," said lead researcher Xiaojiang Chen, professor in molecular and computational biology in the USC College of Letters, Arts and Sciences.

Sometimes called the "Guardian of the Genome," a damaged p53 can leave a cell almost defenseless.

"p53 is a very important tumor suppressor that's mutated in a vast majority of all cancers," said James Pipas, professor of biological sciences at the University of Pittsburgh.

It was Pipas who, after studying LTag for many years and marveling at its varied biological functions – including highly efficient tumor promotion – named it "The Most Amazing Molecule in the Universe" in one of his presentations.

Pipas called Chen's new study "a very important piece of work" that shows how a healthy cell's tumor defenses break down.

"Understanding exactly how this works is going to be a critical step toward our understanding of tumor genesis," he said.

This, in turn, may lead to new techniques for designing tumor-fighting drugs, Pipas added.

Chen's team was able to describe the interplay between LTag and p53 by crystallizing the complex of one LTag and six p53 molecules, totaling more than 50,000 atoms between them.

"It's quite a technical achievement, because these are fairly large proteins," Pipas said.

Chen said his study gave him new respect for LTag and its parent, Simian Virus 40. SV40 has long been used as a research tool to induce cancers in cell cultures.

"Somehow this virus knows how important p53 is, and has this oncoprotein (LTag) to target it by physically interacting with it and changing its conformation," Chen said.

If the virus succeeds, the result is a new tumor.

Source: University of Southern California

Senescence in liver cells can provoke a beneficial immune reaction
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.
Researchers discover how tumor suppressor inhibits cell growth
Genes that inhibit the spontaneous development of cancer are called tumor suppressor genes. One of the major tumor suppressors is p53, a protein that acts in the cell nucleus to control the expression of other genes whose products can inhibit cell proliferation (increase in cell number) and cell growth (increase in cell size). Abnormal cell proliferation and growth are characteristics of cancer. Scientists previously knew which p53 target genes inhibit cell proliferation, but those required for inhibition of cell growth were unknown.
A new cellular pathway linked to cancer is identified
In the life of a cell, the response to DNA damage determines whether the cell is fated to pause and repair itself, commit suicide, or grow uncontrollably, a route leading to cancer. In a new study, published in the July 25th issue of Cell, scientists at NYU Langone Medical Center have identified a way that cells respond to DNA damage through a process that targets proteins for disposal. The finding points to a new pathway for the development of cancer and suggests a new way of sensitizing cancer cells to treatment.
Study of dark-skinned mice leads to protein linked to bone marrow failure in humans
The study of dark-skinned mice has led to a surprising finding about a common protein involved in tumor suppression, report researchers at the Stanford University School of Medicine. The results may lead to new treatments for bone marrow failure in humans.
New cancer treatment targets both tumor cells and blood vessels
MU researchers develop nontoxic treatment that has broad anti-cancer potential
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough. Now, in a new study, University of Missouri researchers have developed a new non-toxic treatment that effectively reduces breast cancer cells, by combining a small molecular drug that targets tumor cells with an antibody that causes selective shutdown of tumor blood vessels.
Novel model of osteosarcoma
In the June 15th issue of G&D, Dr. Stuart Orkin (HHMI, Dana-Farber Cancer Institute, Children's Hospital Boston) and colleagues present a new mouse model of osteosarcoma.
Gene therapy increases survival for end-stage head and neck cancer
A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.
Researchers find roadmap to next-generation cancer therapies
Pinpointing new targets for cancer treatments is as difficult as finding a needle in a haystack, yet a University of Rochester team has discovered an entire novel class of genes they believe will lead to a greater understanding of cancer cell function and the next generation of effective and less harmful therapies for patients.

Cell's fight against cancer revealed

Related stories:

News discussion: